Navigation Links
Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
Date:3/27/2009

SHENZEN, China, March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009.

The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).

Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Microsurgery May Cut Swelling After Breast Cancer Treatment
2. Treatment Target for Herpes Pinpointed
3. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
4. Individualized stroke treatment available for patients, though underutilized
5. New Guidelines for Treating Heart Failure
6. New OTC Allergy Treatment Available to Food Allergy Sufferers
7. Combating weight gain caused by antipsychotic treatments
8. Autism Study Finds Significant Benefit with Hyperbaric Treatment
9. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. Autism Website Relaunches to Offer Resources, Treatments and Hope for Families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Anyone with a remote control has seen ... can do it, you the flipper will get rich in no time. But what ... wrong things can get for the buyer of a flipped house. An email recently ...
(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... ... 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) (TSX.V: ... study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium and ... groundwater. As a part of the study, batch adsorption experiments were conducted with ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... a cosmetic treatment, according to survey data released today by the American ... Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic medical ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... Kohll,s Pharmacy & Homecare is the first distributor of ... . The Raizer is a simple battery operated mobile ... an almost-standing position within a few minutes. The ... and does not require any extra effort besides a ... can operate it, and lightweight and portable so ...
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/30/2017)... TEL AVIV, Israel , May 30, 2017 /PRNewswire/ ... clinical stage pharmaceutical Company specializing in the development ... management will present a company overview at three ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: